HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
HeartSciences (NASDAQ: HSCS) has launched its MyoVista Insights™ platform, a cloud-native ECG Management System designed to enhance clinical decision-making and healthcare IT efficiency. The platform features vendor-agnostic integration capabilities for AI-ECG algorithms, a unique prioritization system, and standardized ECG reporting protocols.
Key features include patient-centric longitudinal comparisons, disease progression tracking, and enhanced workflow efficiency. Built on AWS technology stack, MyoVista Insights offers a pay-as-you-go model, reducing implementation and storage costs compared to legacy systems. The platform will integrate both company-developed and third-party AI-ECG algorithms in future releases to help identify patients requiring further cardiac testing earlier.
HeartSciences (NASDAQ: HSCS) ha lanciato la piattaforma MyoVista Insights™, un sistema di gestione ECG basato su cloud progettato per migliorare il processo decisionale clinico e l'efficienza dell'IT sanitario. La piattaforma offre capacità di integrazione indipendenti dal fornitore per algoritmi AI-ECG, un sistema unico di prioritizzazione e protocolli standardizzati per la refertazione ECG.
Le funzionalità principali includono confronti longitudinali centrati sul paziente, monitoraggio della progressione delle malattie e un miglioramento dell'efficienza dei flussi di lavoro. Realizzata sulla tecnologia AWS, MyoVista Insights propone un modello pay-as-you-go, riducendo i costi di implementazione e archiviazione rispetto ai sistemi tradizionali. Nelle future versioni, la piattaforma integrerà algoritmi AI-ECG sviluppati internamente e di terze parti per identificare precocemente i pazienti che necessitano di ulteriori test cardiaci.
HeartSciences (NASDAQ: HSCS) ha lanzado su plataforma MyoVista Insights™, un sistema de gestión de ECG nativo en la nube diseñado para mejorar la toma de decisiones clínicas y la eficiencia de TI en salud. La plataforma cuenta con capacidades de integración independientes del proveedor para algoritmos AI-ECG, un sistema único de priorización y protocolos estandarizados de informes ECG.
Entre sus características clave se incluyen comparaciones longitudinales centradas en el paciente, seguimiento de la progresión de enfermedades y una mayor eficiencia en el flujo de trabajo. Construida sobre la tecnología AWS, MyoVista Insights ofrece un modelo de pago por uso, reduciendo costos de implementación y almacenamiento en comparación con los sistemas heredados. En futuras versiones, la plataforma integrará algoritmos AI-ECG desarrollados por la empresa y terceros para identificar antes a los pacientes que requieren pruebas cardíacas adicionales.
HeartSciences (NASDAQ: HSCS)는 임상 의사 결정 및 의료 IT 효율성을 향상시키기 위해 설계된 클라우드 기반 심전도(ECG) 관리 시스템인 MyoVista Insights™ 플랫폼을 출시했습니다. 이 플랫폼은 공급업체에 구애받지 않는 AI-ECG 알고리즘 통합 기능, 독특한 우선순위 지정 시스템, 표준화된 ECG 보고 프로토콜을 갖추고 있습니다.
주요 기능으로는 환자 중심의 장기 비교, 질병 진행 추적, 향상된 워크플로우 효율성이 포함됩니다. AWS 기술 스택 위에 구축된 MyoVista Insights는 기존 시스템에 비해 구현 및 저장 비용을 줄이는 종량제(pay-as-you-go) 모델을 제공합니다. 향후 버전에서는 회사 개발 및 타사 AI-ECG 알고리즘을 통합하여 추가 심장 검사가 필요한 환자를 조기에 식별하는 데 도움을 줄 예정입니다.
HeartSciences (NASDAQ : HSCS) a lancé sa plateforme MyoVista Insights™, un système de gestion ECG natif cloud conçu pour améliorer la prise de décision clinique et l'efficacité des systèmes d'information en santé. La plateforme offre des capacités d'intégration indépendantes du fournisseur pour les algorithmes AI-ECG, un système unique de priorisation et des protocoles standardisés de rapport ECG.
Les principales fonctionnalités incluent des comparaisons longitudinales centrées sur le patient, le suivi de la progression des maladies et une meilleure efficacité des flux de travail. Construite sur la technologie AWS, MyoVista Insights propose un modèle de paiement à l'utilisation, réduisant les coûts d'implémentation et de stockage par rapport aux systèmes traditionnels. Les futures versions intégreront des algorithmes AI-ECG développés en interne et par des tiers pour aider à identifier plus tôt les patients nécessitant des examens cardiaques complémentaires.
HeartSciences (NASDAQ: HSCS) hat seine Plattform MyoVista Insights™ vorgestellt, ein cloud-natives ECG-Management-System, das darauf ausgelegt ist, klinische Entscheidungen zu verbessern und die Effizienz der Gesundheits-IT zu steigern. Die Plattform verfügt über herstellerunabhängige Integrationsmöglichkeiten für AI-ECG-Algorithmen, ein einzigartiges Priorisierungssystem und standardisierte ECG-Berichtsprotokolle.
Wesentliche Merkmale sind patientenorientierte Langzeitvergleiche, Verfolgung des Krankheitsverlaufs und verbesserte Arbeitsabläufe. Basierend auf der AWS-Technologie bietet MyoVista Insights ein Pay-as-you-go-Modell, das Implementierungs- und Speicherkosten im Vergleich zu Altsystemen senkt. Künftige Versionen werden sowohl firmeneigene als auch Drittanbieter-AI-ECG-Algorithmen integrieren, um Patienten, die weitere Herzuntersuchungen benötigen, früher zu identifizieren.
- Cloud-native platform reduces total cost of ownership with pay-as-you-go model
- First vendor-agnostic ECG management platform capable of running multiple AI-ECG algorithms
- Advanced cybersecurity features built on AWS technology stack
- Future integration of AI-ECG algorithms will enhance early detection capabilities
- AI-ECG algorithm integration features not yet available in current release
- Limited to select reference sites through early adopter program initially
Insights
HeartSciences launches cloud-based ECG management platform with unique vendor-agnostic design; future AI integration planned amid positive early feedback.
HeartSciences' new MyoVista Insights™ platform represents a significant advancement in ECG management technology with several standout features addressing longstanding industry pain points. The platform's vendor-agnostic architecture is particularly noteworthy as most existing ECG management systems are closed ecosystems, forcing providers into single-vendor relationships. By designing a system that can run AI algorithms from multiple developers, HeartSciences is positioning itself at the center of the emerging AI-ECG ecosystem rather than competing directly with algorithm developers.
From a technical perspective, the AWS-based cloud infrastructure offers substantial advantages over legacy on-premise systems that dominate many healthcare facilities. The pay-as-you-go model eliminates large upfront capital expenditures and ongoing maintenance costs that burden healthcare IT budgets. This approach aligns with healthcare's broader shift toward operational expenditure models for technology procurement.
The platform's longitudinal comparison capabilities address a critical clinical need in cardiology. ECGs are typically evaluated in isolation, making subtle disease progression difficult to detect. The ability to standardize ECG reporting protocols should improve consistency in interpretation, potentially reducing diagnostic variability between providers.
While the current release focuses on ECG management functionality, the roadmap for future AI integration points to HeartSciences' longer-term vision of transforming the diagnostic value of ECGs. The early adopter program approach is standard for healthcare IT implementations, allowing for real-world validation before wider deployment.
HeartSciences begins commercialization phase with SaaS ECG platform launch, establishing revenue path while building toward future AI integration capabilities.
This product launch marks HeartSciences' transition from development to commercialization, establishing a potential recurring revenue stream through their SaaS-based approach. The early adopter program represents a prudent go-to-market strategy for healthcare technology, where reference customers drive broader market adoption. This approach minimizes initial capital outlay while generating valuable implementation data and testimonials.
The pay-as-you-go model positions HeartSciences in the growing healthcare SaaS market, which offers more predictable revenue streams and typically higher multiples than traditional medical device models. By focusing on both clinical and IT benefits, the company addresses decision-makers on both sides of healthcare purchasing.
Strategically, the platform's vendor-agnostic design for future AI algorithm integration creates potential for partnership revenue beyond direct subscriptions. This positions HeartSciences as a potential ecosystem hub rather than just another algorithm developer in the increasingly crowded AI-ECG space.
While the current version lacks the promised AI capabilities, establishing the infrastructure and workflow platform first is a sound approach. The standardized reporting and longitudinal comparison features deliver immediate clinical value while building toward the more sophisticated AI capabilities planned for future releases.
The international testimonials (UK and US) suggest HeartSciences is positioning for a multi-market strategy rather than focusing solely on the US healthcare system. This platform approach with future AI integration represents a transition from traditional medical device models toward a higher-margin software business with ecosystem potential.
Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites.
MyoVista Insights is a cloud-native next-generation ECG Management System designed to enhance both clinical decision-making and healthcare IT efficiency. It will integrate company developed and third-party AI-ECG algorithms as part of future releases and the current platform offers a robust set of features that streamline ECG workflows and reduce costs for healthcare providers.
“I like it… You had me at hello, but you really, you REALLY, had me with the comparisons. That is just outstanding!”
— Dr. Matt Fay, Clinical Director of Cardiology, Westcliffe Health Innovations, U.K.
MyoVista Insights is the first vendor-agnostic ECG management platform designed to run AI-ECG algorithm models from multiple development partners. It features a unique prioritization system and incorporates a standardized ECG reporting protocol which provides a structured and consistent approach to ECG interpretation. Additionally, it includes display protocols specifically designed to enable patient-centric longitudinal comparisons and help track disease progression over time.
“Extremely user-friendly, even for someone who struggles with technology!”
— Chrissy Davis, Nurse Practitioner and owner Embody Health Texas
MyoVista Insights ensures intuitive workflows and enhanced user experience and is built to meet the needs of both clinicians and healthcare IT professionals. For clinicians, MyoVista Insights offers enhanced ECG usability, a patient-centric design, and improved workflow efficiency. MyoVista Insights will significantly increase the clinical value of ECGs by hosting a suite of AI-ECG algorithms in future releases that assist in identifying patients earlier that need further cardiac testing. For healthcare IT teams, it delivers advanced cybersecurity at a reduced total cost of ownership. MyoVista Insights is built on a secure and modern AWS technology stack that meets the highest data security and compliance standards. With a pay-as-you-go model, MyoVista Insights eliminates many costs associated with legacy ECG Management Systems significantly lowering costs to implement, manage and store ECG records.
“We are grateful to all the U.S and international healthcare organizations and professionals that have provided considerable input in the development of MyoVista Insights. It has been designed to radically upgrade ECG management systems and provide wide ranging access to AI-ECG. Feedback has been nothing short of phenomenal and we look forward to working with institutions as part of our early adopter program,” commented Andrew Simpson CEO.
For more information about MyoVista Insights https://www.heartsciences.com or X: @HeartSciences and for early adoption opportunities email info@heartsciences.com
About HeartSciences
HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 29, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2024, filed with the SEC on September 12, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024, filed with the SEC on December 16, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2025, filed with the SEC on March 13, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski
Partner
Phone: 877-255-8483
Email: mkomonoski@integcom.us
Media Contact
HeartSciences
Gene Gephart
+1-682-244-2578 Ext. 2024
info@heartsciences.com
FAQ
What is HeartSciences' MyoVista Insights platform and what does it do?
How does HSCS's MyoVista Insights platform reduce healthcare costs?
What are the key features of HeartSciences' MyoVista Insights platform?
When will HSCS integrate AI algorithms into MyoVista Insights?
How does MyoVista Insights ensure data security and compliance?
